Tvardi Therapeutics, Inc. $TVRD

By Microcap Ledger desk · CIK 0001346830

Facts as of Oct 11, 2026, 08:16 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Pharmaceutical Preparations
Headquarters: Sugar Land, TX
Fiscal year end: December 31
Shares outstanding: 13,338,943 [10-Q 2026-08-14]
as of 2026-08-11

Sources: [10-K 2026-03-31]

What the company doesAI summary of filing

Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral, small-molecule STAT3 inhibitors to treat inflammatory and proliferative diseases. The company's pipeline includes TTI-101, currently in Phase 1b/2 development for hepatocellular carcinoma, and TTI-109, a prodrug of TTI-101 that entered Phase 1 testing in healthy volunteers in June 2025. Tvardi has not generated revenue to date and relies on preclinical and clinical data to advance its candidates. The company is funded through equity financing and has material doubts about its ability to continue as a going concern. [10-K 2026-03-31]

Segments: TTI-101 (STAT3 inhibitor for HCC and IPF), TTI-109 (phosphate prodrug of TTI-101)

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$13.26M	−$15.09M	$15.77M	[10-Q 2026-08-14]
FY ended Dec 2025	—	−$18.21M	−$23.50M	$20.73M	[DEF 14A 2026-04-23]
FY ended Dec 2024	$7.14M	−$29.40M	−$18.30M	$31.61M	[10-K 2025-03-11]

Quarterly cash burn: −$7.54M
Cash runway Estimate: ~6.3 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-11	54,855,514	[10-Q 2024-11-14]
2025-03-06	4,573,606	[10-K 2025-03-11]
2025-05-08	9,360,904	[10-Q 2025-05-13]
2025-08-08	9,377,433	[10-Q 2025-08-14]
2025-11-10	9,381,344	[10-Q 2025-11-13]
2026-03-26	9,381,344	[10-K 2026-03-31]
2026-05-05	9,381,344	[10-Q 2026-05-08]
2026-08-11	13,338,943	[10-Q 2026-08-14]

Shelf registration: S-3 filed 2026-05-01; declared effective 2026-05-12 [S-3 2026-05-01]

Listing status

Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2024-11-22. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2024-11-22	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2024-11-22]

More on deficiency notices and uplistings: Listing status desk.

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-08-14	10-Q	Quarterly report
2026-08-14	8-K	Results of operations
2026-07-30	8-K	Regulation FD disclosure
2026-07-17	8-K	Other events
2026-07-17	424B5	Prospectus or prospectus supplement
2026-07-07	8-K	Regulation FD disclosure
2026-06-11	8-K	Shareholder vote results
2026-05-08	10-Q	Quarterly report
2026-05-08	8-K	Results of operations
2026-05-01	S-3	Registration statement
2026-04-23	DEF 14A	Proxy statement
2026-04-01	424B3	Prospectus or prospectus supplement

Facts as of Oct 11, 2026, 08:16 AM UTC. Small caps move fast; check the latest filings.